Literature DB >> 1846724

New approaches to the diagnosis, prevention, and treatment of cytomegalovirus infection after transplantation.

D L Dunn1, J S Najarian.   

Abstract

Infection occurring after solid organ transplantation continues to exert a considerable detrimental effect upon patient and allograft survival. While the search for better targeted immunosuppressive regimens continues, we must seek to improve our ability to both diagnose and treat those infections that do occur after transplantation. Viral infections in general, and cytomegalovirus (CMV) infections in particular, represent an area in which substantial progress is being made. Improvement in diagnostic modalities has allowed more rapid and precise identification of CMV infection and disease, and the use of antiviral agents that possess activity against CMV has allowed both prophylaxis and treatment of this frequently life-threatening disease. The prophylactic use of presently available agents in combination and the development of less toxic, more potent anti-CMV agents should serve to further lessen the impact of CMV disease upon the field of solid organ transplantation.

Entities:  

Mesh:

Year:  1991        PMID: 1846724     DOI: 10.1016/0002-9610(91)91140-e

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Investigation of novel LPS-induced differentially expressed long non-coding RNAs in endothelial cells.

Authors:  Krishna K Singh; Pratiek N Matkar; Shoaib Muhammad; Adrian Quan; Vijay Gupta; Hwee Teoh; Mohammed Al-Omran; Subodh Verma
Journal:  Mol Cell Biochem       Date:  2016-08-26       Impact factor: 3.396

2.  Human cytomegalovirus DNA in cerebrospinal fluid.

Authors:  J Kohyama; M Kajiwara; M Shimohira; Y Iwakawa; H Okawa
Journal:  Arch Dis Child       Date:  1994-11       Impact factor: 3.791

Review 3.  Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.

Authors:  A Markham; D Faulds
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.